Molecubes
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
EBITDA | (<1m) | <1m | <1m | 1.5m | 1.1m | 2.7m | - |
Profit | (<1m) | <1m | <1m | 1.3m | 1.0m | 2.6m | 2.8m |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
* | N/A | €2.0m | Seed |
* | N/A | Acquisition | |
Total Funding | AUD3.4m |
Related Content
Recent News about Molecubes
EditMOLECUBES specializes in the design and manufacture of advanced preclinical imaging systems, specifically PET, SPECT, and CT scanners, aimed at researchers and laboratory scientists. Operating in the niche market of molecular small animal imaging, MOLECUBES provides solutions that deliver high-quality images with fast and straightforward workflows. Their flagship products, the X CUBE series, are known for being the most compact in the industry, offering both standalone and modular configurations. The company's benchtop design and innovative service concepts make their imaging systems user-friendly and efficient. MOLECUBES generates revenue through the direct sale of these high-end imaging systems to research institutions, universities, and pharmaceutical companies. The business model focuses on providing cutting-edge technology that supports detailed in vivo imaging studies, particularly in neurology and other biomedical research fields.
Keywords: preclinical imaging, PET scanners, SPECT scanners, CT scanners, small animal imaging, modular systems, benchtop design, high-resolution imaging, research laboratories, biomedical research.